by Plus Therapeutics | Nov 26, 2025 | GBM
Innovations in brain cancer treatment continue to advance, fueled by the dedication of leading clinicians and researchers across the globe. In the latest episode of the Game On Glio podcast, Toral Patel, MD (UT Southwestern Medical Center) and Andrew Brenner, MD, PhD...
by Plus Therapeutics | Nov 14, 2025 | GBM
Plus Therapeutics is proud to share that the ReSPECT-GBM clinical trial is now a featured study on the American Brain Tumor Association (ABTA) website. This recognition highlights the growing visibility and clinical importance of our work to develop new therapeutic...
by Plus Therapeutics | Sep 17, 2025 | GBM, PBC
Each September, Childhood Cancer Awareness Month (#CCAM) serves as a powerful reminder to honor children and families affected by pediatric cancer and to raise awareness for the urgent need for new treatment options. At Plus Therapeutics (Nasdaq: PSTV), we are deeply...
by Plus Therapeutics | Aug 7, 2025 | GBM
Glioblastoma (GBM) is one of the most aggressive and challenging forms of brain cancer, with limited treatment options available today. At Plus Therapeutics (NASDAQ: PSTV), we are committed to developing new therapies that can bring hope to patients and their...
by Plus Therapeutics | Jul 22, 2025 | GBM
Each year on World Brain Day, the World Federation of Neurology (WFN) shines a global spotlight on the importance of brain health and the burden of neurological disorders. In 2025, this important observance carries the theme “Brain Health for All Ages”,...
by Plus Therapeutics | Jul 16, 2025 | GBM
As we continue to honor GBM Awareness Day, Plus Therapeutics is proud to spotlight new insights from our RESPECT-GBM Phase 2 clinical trial—research aimed at addressing the urgent need for better treatment options for patients with recurrent glioblastoma (GBM). In a...
Recent Comments